As the coronavirus disease 2019 (COVID-19) pandemic has progressed, a large volume of
literature has developed delineating the clinical manifestations of acute infection. Recent …

Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated
inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, …

Background Functional impairment of interferon, a natural antiviral component of the
immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to …

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …

… Akamine CM, El Sahly HM. Messenger ribonucleic acid vaccines for severe acute
respiratory syndrome coronavirus-2: a review. Transl Res 2022; 242:1–19. … Baden LR, El …

Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …